Valeant CEO sees new drug pricing environment ahead
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St set to open lower as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Goldman sees central bank demand providing a floor for gold prices
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
Jefferies Cuts Price Target to $224 Following Valeant Pharma (VRX) 3Q EPS Beat
October 20, 2015 10:22 AM EDTJefferies maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $224.00 (from $294.00), following the company's 3Q results. VRX reported revenues of $2.79B vs the Street's $2.78B. EPS was reported at $2.74 vs the Street's $2.72.
Analyst David Steinberg... More
CIBC Downgrades Valeant Pharmaceuticals (VRX) to Sector Perform
October 20, 2015 7:26 AM EDTCIBC downgraded Valeant Pharmaceuticals (NYSE: VRX) from Sector Outperform to Sector Perform.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $163.83 yesterday.
... MoreMizuho Securities Remains Neutral After Valeant Pharma (VRX) Reports 2c EPS Beat
October 20, 2015 6:46 AM EDTMizuho Securities reiterates a Neutral rating and $155.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's 3Q earnings report. Revenues of $2.80B beat consensus estimates of $2.79B and EPS of $2.74 came in $0.02 higher. Management raised full year revenue guidance to $11.0-$11.2B and... More
BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance
October 20, 2015 6:42 AM EDTBMO Capital maintained an Outperform rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $265.00 (from $273.00), following the company's 3Q15 earnings results. VRX beat expectations for the quarter, however, the results showed that the legacy business had underperformed.
Analyst Alex Arfaei... More
